Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.
Schröder L, Rack B, Sommer H, Koch JG, Weissenbacher T, Janni W, Schneeweiss A, Rezai M, Lorenz R, Jäger B, Schramm A, Häberle L, Fasching PA, Friedl TW, Beckmann MW, Scholz C. Schröder L, et al. Among authors: weissenbacher t. Geburtshilfe Frauenheilkd. 2016 May;76(5):542-550. doi: 10.1055/s-0042-106209. Geburtshilfe Frauenheilkd. 2016. PMID: 27239063 Free PMC article.
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Widschwendter P, Friedl TW, Schwentner L, DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K, Weissenbacher T, Kost B, Andergassen U, Jueckstock J, Neugebauer J, Trapp E, Fasching PA, Beckmann MW, Schneeweiss A, Schrader I, Rack B, Janni W, Scholz C. Widschwendter P, et al. Among authors: weissenbacher t. Breast Cancer Res. 2015 Sep 18;17(1):129. doi: 10.1186/s13058-015-0639-3. Breast Cancer Res. 2015. PMID: 26385214 Free PMC article. Clinical Trial.
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.
Schwentner L, Harbeck N, Singer S, Eichler M, Rack B, Forstbauer H, Wischnik A, Scholz C, Huober J, Friedl TW, Weissenbacher T, Härtl K, Kiechle M, Janni W, Fink V. Schwentner L, et al. Among authors: weissenbacher t. Breast. 2016 Jun;27:69-77. doi: 10.1016/j.breast.2016.03.003. Epub 2016 Apr 4. Breast. 2016. PMID: 27054751 Clinical Trial.
CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
Rack B, Jückstock J, Trapp E, Weissenbacher T, Alunni-Fabbroni M, Schramm A, Widschwendter P, Lato K, Zwingers T, Lorenz R, Tesch H, Schneeweiss A, Fasching P, Mahner S, Beckmann MW, Lichtenegger W, Janni W; SUCCESS Study Group. Rack B, et al. Among authors: weissenbacher t. Tumour Biol. 2016 Oct;37(10):13769-13775. doi: 10.1007/s13277-016-5171-2. Epub 2016 Aug 1. Tumour Biol. 2016. PMID: 27481512 Clinical Trial.
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
Mutschler NS, Scholz C, Friedl TWP, Zwingers T, Fasching PA, Beckmann MW, Fehm T, Mohrmann S, Salmen J, Ziegler C, Jäger B, Widschwendter P, de Gregorio N, Schochter F, Mahner S, Harbeck N, Weissenbacher T, Jückstock J, Janni W, Rack B. Mutschler NS, et al. Among authors: weissenbacher t. Clin Breast Cancer. 2018 Apr;18(2):175-183. doi: 10.1016/j.clbc.2018.01.008. Epub 2018 Jan 31. Clin Breast Cancer. 2018. PMID: 29598955 Clinical Trial.
Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial.
Hepp P, Fasching PA, Beckmann MW, Fehm T, Salmen J, Hagenbeck C, Jäger B, Widschwendter P, de Gregorio N, Schochter F, Mahner S, Harbeck N, Weissenbacher T, Kurt AG, Friedl TWP, Janni W, Rack B. Hepp P, et al. Among authors: weissenbacher t. Clin Breast Cancer. 2018 Oct;18(5):e1103-e1110. doi: 10.1016/j.clbc.2018.06.006. Epub 2018 Jun 18. Clin Breast Cancer. 2018. PMID: 30017795
Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study.
Deniz M, DeGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer EC, Aivazova-Fuchs V, Weissenbacher T, Kost B, Jueckstock J, Andergassen U, Steidl J, Trapp E, Fasching PA, Häberle L, Beckmann MW, Schneeweiss A, Schrader I, Janni W, Rack B, Friedl TW. Deniz M, et al. Among authors: weissenbacher t. Breast. 2019 Apr;44:81-89. doi: 10.1016/j.breast.2018.12.008. Epub 2018 Dec 20. Breast. 2019. PMID: 30690254
Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells.
König A, Vilsmaier T, Rack B, Friese K, Janni W, Jeschke U, Andergassen U, Trapp E, Jückstock J, Jäger B, Alunni-Fabbroni M, Friedl T, Weissenbacher T; SUCCESS STUDY GROUP. König A, et al. Among authors: weissenbacher t. Anticancer Res. 2016 Jun;36(6):3123-30. Anticancer Res. 2016. PMID: 27272837
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies.
Salmen J, Neugebauer J, Fasching PA, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Heil J, Rom J, Sohn C, Fehm T, Mohrmann S, Loehberg CR, Hein A, Schulz-Wendtland R, Hartkopf AD, Brucker SY, Wallwiener D, Friese K, Hartmann A, Beckmann MW, Janni W, Rack B. Salmen J, et al. Among authors: weissenbacher t. Breast Cancer Res Treat. 2014 Nov;148(1):143-51. doi: 10.1007/s10549-014-3130-4. Epub 2014 Sep 25. Breast Cancer Res Treat. 2014. PMID: 25253172
53 results